PegBio Reports No Change in Share Capital for August 2026; Confirms Adequate Public Float

Bulletin Express
Sep 03

PegBio Co., Ltd. released its Monthly Return for Equity Issuer covering the period ended 31 August 2026, showing a stable capital structure and continued compliance with Hong Kong public-float requirements.

Authorised / Registered Capital • Registered share capital stood unchanged at RMB 391.09 million, comprising 386.00 million H-shares and 5.09 million unlisted ordinary shares, each with a par value of RMB 1. • No increase or decrease in registered shares was recorded during the month.

Issued Shares and Public Float • Issued H-shares (excluding treasury shares) remained at 386.00 million; the company held no treasury shares. • Issued unlisted shares remained at 5.09 million. • PegBio confirmed that it met the Main Board Rule 13.32D(1) minimum public-float threshold of 25% as of 31 August 2026.

Capital Instruments and Corporate Actions • The company reported no movements in share options, warrants, convertible securities, or other equity-linked instruments during the month. • No repurchases, cancellations, redemptions, or treasury-share transactions occurred.

Governance • The filing was submitted on 3 September 2026 and signed by Joint Company Secretary Huang Yifeng, affirming the accuracy of the disclosed information.

Key Takeaway PegBio maintained a steady equity base throughout August 2026, with all compliance metrics—including the public-float requirement—fully satisfied and no dilution or capital changes recorded.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10